Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims data.

Stirnadel-Farrant, Heide A; Xu, Xiao; Kwiatek, Justin; Jain, Priya; Meyers, Juliana; Candrilli, Sean; Mines, Daniel; Datto, Catherine J

Stirnadel-Farrant, Heide A; Xu, Xiao; Kwiatek, Justin; Jain, Priya; Meyers, Juliana; Candrilli, Sean; Mines, Daniel; Datto, Catherine J.

Afiliação

Stirnadel-Farrant HA; BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Xu X; BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland.
Kwiatek J; BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland.
Jain P; BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Meyers J; RTI Health Solutions, Research Triangle Park, North Carolina.
Candrilli S; RTI Health Solutions, Research Triangle Park, North Carolina.
Mines D; RTI Health Solutions, Research Triangle Park, North Carolina.
Datto CJ; Late-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.

JAAD Int ; 13: 117-125, 2023 Dec.

Article em En | MEDLINE | ID: mdl-37808963

Palavras-chave

antibiotics; autoimmune disease; blistering skin disease; bullous pemphigoid; burden of disease; clinical characteristics; comorbidity; costs; health care resource utilization; opioids; steroids; treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Risk_factors_studies Idioma: En Revista: JAAD Int Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google